Based on this scenario, overexpression of NLRP3/MyD88 and cytokines during hyperglycemia in breast cancer cells and cardiomyocytes could be a key player in cardiotoxicity and resistance to ipilimumab. This evidence concerns the gene NLRP3 and breast carcinoma.